{"id":168730,"date":"2025-06-10T06:11:17","date_gmt":"2025-06-10T10:11:17","guid":{"rendered":"https:\/\/44.250.171.167\/?p=168730"},"modified":"2025-06-10T06:11:17","modified_gmt":"2025-06-10T10:11:17","slug":"astrazeneca-pharma-india-ltd-q4fy25-3-rise-in-revenue","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q4fy25-3-rise-in-revenue\/","title":{"rendered":"Astrazeneca Pharma India Ltd Q4FY25; 3% rise in Revenue"},"content":{"rendered":"<p>AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.<\/p>\n<p>Financial Results:<\/p>\n<p>Astrazeneca Pharma India Ltd reported Revenues for Q4FY25 of \u20b91,000.00 Crores up from \u20b9974.00 Crore year on year, a rise of 2.67%.<\/p>\n<p>Total Expenses for Q4FY25 of \u20b9914.00 Crores up from \u20b9905.00 Crores year on year, a rise of 0.99%.<\/p>\n<p>Consolidated Net Profit of \u20b986.00 Crores from -\u20b92.00 Crores in the same quarter of the previous year.<\/p>\n<p>The Earnings per Share is \u20b91.58, from -\u20b90.48 in the same quarter of the previous year.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-168731\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q4FY25 of \u20b91,000.00 Crores up from \u20b9974.00 Crore year on year, a rise of 2.67%. Total Expenses for Q4FY25 of \u20b9914.00 Crores up from \u20b9905.00 Crores year on year, [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":168731,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-168730","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":168654,"url":"https:\/\/alphastreet.com\/india\/ajanta-pharma-ltd-q4fy25-11-rise-in-profits\/","url_meta":{"origin":168730,"position":0},"title":"Ajanta Pharma Ltd Q4FY25; 11% rise in Profits","author":"Divyansh_Kasana","date":"June 5, 2025","format":false,"excerpt":"Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70). Financial Results: Ajanta Pharma Ltd reported Revenues for Q4FY25 of \u20b91,170.00 Crores up from \u20b91,054.00 Crore year on year, a rise of 11.01%. Total Expenses for Q4FY25 of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/O-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/O-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/O-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/O-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/O-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/O-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167105,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q3fy25-69-fall-in-profits\/","url_meta":{"origin":168730,"position":1},"title":"Astrazeneca Pharma India Ltd Q3FY25; 69% fall in Profits","author":"Divyansh_Kasana","date":"February 27, 2025","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q3FY25 of \u20b91,050.00 Crores up from \u20b9955.00 Crore year on year, a rise of 9.95%. Total Expenses for Q3FY25 of \u20b9957.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168736,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q4fy25-0-fall-in-profits\/","url_meta":{"origin":168730,"position":2},"title":"Aurobindo Pharma Ltd Q4FY25; 0% fall in Profits","author":"Divyansh_Kasana","date":"June 10, 2025","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159) Financial Results: Aurobindo Pharma Ltd reported Revenues for Q4FY25 of \u20b98,382.00 Crores up from \u20b97,580.00 Crore year on year, a rise of 10.58%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168718,"url":"https:\/\/alphastreet.com\/india\/mankind-pharma-ltd-q4fy25-11-fall-in-profits\/","url_meta":{"origin":168730,"position":3},"title":"Mankind Pharma Ltd Q4FY25; 11% fall in Profits","author":"Chirag Gupta","date":"June 9, 2025","format":false,"excerpt":"Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. Financial Results: Mankind Pharma Ltd reported Revenues for Q4FY25 of \u20b93,079.00 Crores up from \u20b92,422.00 Crore year on year, a rise of 27.13%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-4.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-4.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-4.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-4.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-4.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/2-4.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":154136,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q1fy24-170-rise-in-profits\/","url_meta":{"origin":168730,"position":4},"title":"Astrazeneca Pharma India Ltd Q1FY24; 170% rise in Profits","author":"Divyansh_Kasana","date":"August 16, 2023","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q1FY24 of \u20b9295.00 Crores up from \u20b9232.00 Crore year on year, a rise of 27.16%. Total Expenses for Q1FY24 of \u20b9232.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":157083,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q2fy24-58-rise-in-profits\/","url_meta":{"origin":168730,"position":5},"title":"Astrazeneca Pharma India Ltd Q2FY24; 58% rise in Profits","author":"Divyansh_Kasana","date":"December 4, 2023","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q2FY24 of \u20b9311.00 Crores up from \u20b9236.00 Crore year on year, a rise of 31.78%. Total Expenses for Q2FY24 of \u20b9262.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/168730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=168730"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/168730\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/168731"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=168730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=168730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=168730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}